Oral budesonide as maintenance therapy in Crohn's disease - results of a 12-month study

Alimentary Pharmacology and Therapeutics

Volumn 12, Issue 2, 1998, Pages 175-183

  Ferguson, A ^a,e   Campieri, M ^b   Doe, W ^c   Persson, T ^d   Nygard G ^d  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c Biology and Environment   (Australia)

^d ASTRAZENECA R AND D   (Sweden)

^e WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; PLACEBO;

ACNE; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HAIR GROWTH; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MOON FACE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; SIDE EFFECT; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; BUDESONIDE; CROHN DISEASE; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; GREAT BRITAIN; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; RECURRENCE; TREATMENT OUTCOME;

EID: 0031984919     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1998.00285.x     Document Type: Article

References (15)

1. Elton E, Hanauer SB. Review article: the medical management of Crohn's disease. Aliment Pharmacol Ther 1996; 10: 1-22.
2. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide for active Crohn's disease (Canadian Inflammatory Bowel Disease Study Group). N Engl J Med 1994; 331: 836-41.
3. Rutgeerts P, Löfberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994; 331: 842-5.
4. Campieri M, Ferguson A, Doe W. International Budesonide Study Group. Oral hudesonide competes favourably with prednisolone in active Crohn's disease. Gut 1997; 41: 209-14.
5. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide as maintenance treatment for Crohn's disease: A placebo-controlled, dose-ranging study (Canadian Inflammatory Bowel Disease Study Group). Gastroenterology 1996; 110: 45-51.
6. Löfberg R, Rutgeerts P, Malchow H, et al. Budesonide CIR for maintenance of remission in ileocecal Crohn's disease. A European multicenter placebo controlled trial for 12 months. Gut 1996; 39: 82-6.
7. Best WR, Becktel JM, Singleton JW, Kern F. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 439-44.
8. Malchow H, Ewe K, Brandes JW, et al. European cooperative Crohn's disease study (ECCDS): results of drug treatment. Gastroenterology 1984; 86: 249-66.
9. Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials. J Am Med Assoc 1996; 276: 8, 637-9.
10. Acciuffi S, Ghosh S, Ferguson A. Strengths and limitations of the Crohn's disease activity index, revealed by an objective gut lavage test of gastro-intestinal protein loss. Aliment Pharmacol Ther 1996; 10: 321-6.
11. Bayless TM. Maintenance therapy for Crohn's disease. Editorial. Gastroenterology 1996; 110: 299-302.
12. O'Donoghue DP, Dawson AM, Powell-Tuck J, Bown RL, Lennard-Jones JE. Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. Lancet 1978; 2: 955-7.
13. Thomson ABR. International Mesalazine Study Group. Coated oral 5-aminosalicylic acid vs. placebo in maintaining remission in Crohn's disease. Aliment Pharmacol Ther 1990; 4: 55-64.
14. Prantera C, Pallone F, Brunetti G, Cottone M, Miglioli M. The Italian Inflammatory Bowel Disease Study Group. Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease. Gastroenterology 1992; 103: 563-8.
15. Ferguson A. Ulcerative colitis and Crohn's disease - important and disabling diseases, still under-researched. Br Med J 1994; 39: 355-6.